Stockscreener 앱 받기
2.22
7.25%
0.15
시간 외 거래:
2.23
0.010
+0.45%
전일 마감가:
$2.07
열려 있는:
$2.06
하루 거래량:
191.97K
Relative Volume:
0.48
시가총액:
$57.45M
수익:
$210.70K
순이익/손실:
$-22.22M
주가수익비율:
-1.2198
EPS:
-1.82
순현금흐름:
$-17.13M
1주 성능:
-13.62%
1개월 성능:
+21.98%
6개월 성능:
-25.00%
1년 성능:
-22.65%
1일 변동 폭
$2.0201
$2.30
1주일 범위
$2.0201
$2.58
52주 변동 폭
$0.89
$5.33
게인 테라퓨틱스 Stock (GANX) Company Profile
명칭
Gain Therapeutics Inc
전화
(301) 500-1556
주소
4800 HAMPDEN LANE, BETHESDA
게인 테라퓨틱스 Stock (GANX) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2021-04-12 | 개시 | BTIG Research | Buy |
| 2021-04-12 | 개시 | Oppenheimer | Outperform |
게인 테라퓨틱스 주식(GANX)의 최신 뉴스
2024's 10 Best-Performing Stocks | Investing - U.S News & World Report Money
Hoping for a weight-loss pill? It could get closer to reality next week. - MarketWatch
individual investors who own 55% along with institutions invested in Sangamo Therapeutics, Inc. (NASDAQ:SGMO) saw increase in their holdings value last week - Yahoo Finance
Amneal Pharmaceuticals (NASDAQ:AMRX) grows 3.0% this week, taking five-year gains to 211% - Yahoo Finance
Short Interest in Gain Therapeutics, Inc. (NASDAQ:GANX) Decreases By 12.6% - MarketBeat
Vertex Pharmaceuticals (VRTX) Stock Drops Despite Market Gains: Important Facts to Note - Yahoo Finance
Nuclear stocks gain on AI optimism: Oklo, NuScale, Centrus - Yahoo Finance
Investing in Arcturus Therapeutics Holdings (NASDAQ:ARCT) five years ago would have delivered you a 76% gain - Yahoo Finance
Gain Therapeutics Presents Data at 36ᵗʰ EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics Demonstrating Identification of Allosteric Inhibitors Targeting DDR2 - The Manila Times
What Sangamo Therapeutics, Inc.'s (NASDAQ:SGMO) 26% Share Price Gain Is Not Telling You - Simply Wall St
Gain Therapeutics Regains Nasdaq Compliance - Investing.com
Gain Therapeutics Regains Nasdaq Compliance By Investing.com - Investing.com UK
Viking Therapeutics, Inc. (VKTX) Exceeds Market Returns: Some Facts to Consider - MSN
32 NMEs gain US FDA clearance through Q3, approvals up over 2023 - BioWorld Online
Viking Therapeutics, Inc. (VKTX) Outpaces Stock Market Gains: What You Should Know - MSN
How should investors view Janux Therapeutics Inc (JANX)? - US Post News
What was Gain Therapeutics Inc (GANX)’s performance in the last session? - US Post News
Gain Therapeutics Inc [GANX] Investment Guide: What You Need to Know - Knox Daily
GANX Stock: A Voyage Through Gain Therapeutics Inc’s Finances - The InvestChronicle
Can you now get a good deal on Compass Therapeutics Inc’s shares? - US Post News
Gain Therapeutics Announces Poster Presentation at 36th EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics - The Manila Times
Renaissance Technologies LLC Boosts Holdings in Exagen Inc. (NASDAQ:XGN) - Defense World
Renaissance Technologies LLC Has $152,000 Stock Position in Gain Therapeutics, Inc. (NASDAQ:GANX) - Defense World
Investing in Voyager Therapeutics (NASDAQ:VYGR) three years ago would have delivered you a 58% gain - Yahoo Finance
Boeing, Nurix Therapeutics And 3 Stocks To Watch Heading Into Monday - Benzinga
Edgewise Therapeutics Inc (EWTX) Stock: Navigating Drops and Gains - The InvestChronicle
Seres Therapeutics gains amid takeover speculation - Seeking Alpha
GT-02287 may slow Parkinson’s progression, new early data suggest - Parkinson's News Today
Soleno Therapeutics Inc [SLNO] Revenue clocked in at $0.00 million, up 29.12% YTD: What’s Next? - The DBT News
PTC Therapeutics (PTCT) Surges 16.5%: Is This an Indication of Further Gains? - Yahoo
Gain Therapeutics to Present at Michael J. Fox Foundation's 16th Annual Parkinson's Disease Therapeutics Conference - The Manila Times
Gain Therapeutics to Present at Michael J. Fox Foundation’s 16th Annual Parkinson’s Disease Therapeutics Conference - Yahoo Finance
Belite Delights Investors, Soleno, ADMA, Harrow Deliver Triple-digit Gains, Keep An Eye On Oculis - RTTNews
Gain Therapeutics Announces Positive Preclinical Data for GT-02287 - Defense World
CRISPR Therapeutics AG (CRSP) Stock Sinks As Market Gains: Here's Why - Yahoo Finance
Gain Therapeutics Excels in Neurodegenerative Drug Trials - TipRanks
Gaining Ground: Aptevo Therapeutics Inc (APVO) Closes Lower at 0.16, Down -2.60 - The Dwinnex
GANX’s Financial Health: Exploring Gain Therapeutics Inc’s Debt-to-Equity Ratio of 1.79 - The InvestChronicle
Can you still get a good price for Mersana Therapeutics Inc (MRSN) Shares at this point? - US Post News
Robinhood Markets Inc [HOOD] Stock sold by Insider Gallagher Daniel Martin Jr for $0.28 million - Knox Daily
GT-02287 shows promise in Parkinson's disease models - Investing.com
Small-Cap Gain Therapeutics Stock Falls On Phase 1 Data From Its Lead Asset For Parkinson's Disease - MSN
Three startups aim to raise $400 million as US biotech IPOs gain traction - Yahoo Finance
Market Insight: Fate Therapeutics Inc (FATE)’s Notable Gain, Closing at 3.22 - The Dwinnex
Three startups aim to raise $400 mln as US biotech IPOs gain traction - Reuters
Gaining Ground: Seres Therapeutics Inc (MCRB) Closes Higher at 0.85, Up 1.35 - The Dwinnex
Gain Therapeutics Presents Preclinical GT-02287 Data at Neuroscience 2024 - The Manila Times
GT-02287 shows promise in Parkinson's disease models By Investing.com - Investing.com UK
Can you still get a good price for Denali Therapeutics Inc (DNLI) Shares at this point? - US Post News
Applied Therapeutics Inc (APLT) Stock: A 52-Week Tale of Drops and Gains - The InvestChronicle
Gain Therapeutics to Participate at Upcoming Investor Conferences - The Manila Times
게인 테라퓨틱스 (GANX) 재무 분석
매출
순이익
현금흐름
주당 순 이익
2.02%
0.47%
자본화:
|
볼륨(24시간):